CVE-2026-48353 CAI Content Credentials | Improper Input Validation (CWE-20)
An attacker can read sensitive files outside the intended scope by tricking a user into opening a malicious file with the Content Credentials tool.
- Exploited in the wild
- Not known
- Login needed
- Not needed
- Attackable
- Local or same network only
- Victim action needed
- A user has to click or open something
- Fix
- None listed
What is CVE-2026-48353?
CVE-2026-48353 is a medium-severity path traversal vulnerability in Adobe C2pa, published on 14 Jul 2026. It can only be exploited from the same machine or local network, and only if a user opens a file or follows a link.
Official description
CAI Content Credentials is affected by an Improper Input Validation vulnerability that could lead to arbitrary file system read. An attacker could exploit this vulnerability to access sensitive files and directories outside the intended access scope. Exploitation of this issue requires user interaction in that a victim must open a malicious file.
Weakness: CWE-20
Which versions are affected by CVE-2026-48353?
It affects 3 products.
Products include Adobe C2pa, Adobe C2pa-Web, Adobe C2patool.
How do I fix CVE-2026-48353?
No fix has been published for CVE-2026-48353 yet. Limit exposure of the affected software until one is available.
Upgrade, and resolve every user-supplied path against an allowed base folder before opening it. More about Path traversal.
Is CVE-2026-48353 being exploited?
There is no known exploitation of CVE-2026-48353 in the wild and no public exploit code.
Other vulnerabilities in Adobe C2pa
- CVE-2026-95634 CAI Content Credentials | Server-Side Request Forgery (SSRF) (CWE-918)
- CVE-2026-48290 CAI Content Credentials | Server-Side Request Forgery (SSRF) (CWE-918)
- CVE-2026-100113 CAI Content Credentials | Improper Input Validation (CWE-20)
- CVE-2026-100114 CAI Content Credentials | Improper Access Control (CWE-284)
- CVE-2026-100115 CAI Content Credentials | Improper Access Control (CWE-284)
Sources
Also known as GHSA-c279-wrgp-v9mg.